General Investing >> Money Manager Interviews >> September 4, 2020

Using an Exchange-Traded Fund to Invest in Infectious Disease

Masucci, Samuel
Samuel Masucci is Chief Executive Officer and Founder of Exchange Traded Managers Group, LLC. Mr. Masucci has more than 25 years’ experience in investment banking, structured product development, sales and trading. In the last five years, he founded ETF Managers Group — ETFMG — to revolutionize the exchange-traded fund marketplace. Mr. Masucci’s leadership has already led to the successful launch of 14 funds and $4 billion in assets. His unique approach to the ETF go-to-market process and post-launch management is setting the bar in this quickly evolving industry. Prior to ETFMG, he has held senior positions at Bear Stearns, UBS, SBC Warburg and Merrill Lynch, and has a proven track record of creating, building and managing businesses for the issuance, sales and trading of: ETFs, index products, commodity products, hedge funds, ABS and OTC structured products in the U.S. and Europe. He has significant experience in asset management product sales to institutional investors, including pension funds, consultants, insurance companies and hedge funds as well as to broker/dealer networks and RIAs. Profile
Panettieri Jr., Reynold A.
Reynold A. Panettieri Jr., M.D., Expert, GERM of Exchange Traded Managers Group, LLC as well as Vice Chancellor, Translational Medicine and Science, and Director, Rutgers Institute for Translational Medicine and Science. Dr. Panettieri, in addition to being the named expert to the ETFMG Treatments, Testing and Advancements ETF (NYSEARCA:GERM), is Professor of Medicine, Vice Chancellor for Translational Medicine and Science at Rutgers University and the Director of the Institute for Translational Medicine and Science. Previously, he was the Robert L. Mayock and David A. Cooper Professor of Medicine in the Pulmonary, Allergy and Critical Care Division of the Department of Medicine and served as Deputy Director of the Center of Excellence in Environmental Toxicology at the University of Pennsylvania Perelman School of Medicine where he remains professor emeritus. Dr. Panettieri is also the recipient of numerous honors and awards, including the Robert E. Cooke Memorial Lectureship at the American Academy of Allergy, Asthma and Immunology Annual Meeting, the Joseph R. Rodarte Award for Scientific Distinction and the Recognition Award for Scientific Accomplishments from the American Thoracic Society, or ATS. He is also an active member of national professional and scientific societies including the American College of Chest Physicians and ATS; in 2013, he was elected Chair of the Respiratory Structure and Function Assembly of ATS. Dr. Panettieri served as Chair of the NIH Lung Cellular, Molecular and Immunobiology Study Section; is a member of the NIH Distinguished Editorial Panel; and is a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Panettieri is principal investigator on several NIH-sponsored grants and industry-sponsored clinical studies, is director of a program project grant examining novel approaches in modulating G protein-coupled receptor function and is the principal investigator of the CTSA Hub entitled “New Jersey Alliance for Clinical and Translational Science.” He is the author of over 475 peer-reviewed publications. Dr. Panettieri manages the comprehensive clinical care of patients with asthma and is engaged in clinical investigations focused on the management of asthma and COPD. Profile
Word count: 3,644

TWST: You have spoken to us before of course but, for the uninitiated, provide a brief overview of ETF Managers Group. You have mentioned how, unlike other groups that